Akineton® (Akineton®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceBiperidenBiperiden
Similar drugsTo uncover
  • Akineton®
    solution w / m in / in 
    Desma GmbH     Germany
  • Akineton®
    pills inwards 
    Desma GmbH     Germany
  • Bezac®
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Mendilex®
    pills inwards 
    Alkaloid, JSC     Macedonia
    • Dosage form: & nbsppills
    Composition:

    For one tablet:

    active substance; biperidene hydrochloride 2.0 mg;

    Excipients: corn starch, lactose monohydrate, microcrystalline cellulose, calcium hydrogen phosphate dihydrate, potato starch, copovidone, talc, magnesium stearate, purified water.

    Description:

    Almost white, flat-cylindrical tablets, on one side of which there is a cruciform risk, with chamfers.

    Pharmacotherapeutic group:Hollow block central
    ATX: & nbsp

    N.04.A.A.02   Biperiden

    Pharmacodynamics:

    Biperiden is the central anticholinergic agent, reduces the activity of the cholinergic neurons of the striatum (the structural component of the extrapyramidal system). Peripheral anticholinergic action is less pronounced. Reduces tremors and stiffness. Biperiden causes psychomotor agitation, vegetative disorders.

    Pharmacokinetics:

    The time to reach the maximum concentration after ingestion and the maximum concentration are respectively 0.5-2 h (1.01-6.53 ng / ml). The equilibrium concentration when ingestion 2 mg twice a day is reached after 15.7-40.7 hours.The connection with plasma proteins is 91-94%. Plasma clearance is 11.6 ± 0.8 ml / min / kg of body weight. Bioavailability after a single oral intake is about 33 ± 5%. Penetrates into breast milk.

    Biperiden is completely metabolized. The main metabolites, bicycloheptane and piperidine, are excreted in urine and feces.

    Excretion is carried out in two phases with a half-life (T1/2) 1,5 h in the first phase and 24 h in the second, in elderly patients the half-life can increase up to 38 h.

    Indications:

    - Parkinsonism syndrome in adults;

    - extrapyramidal symptoms in children and adults caused by neuroleptics or similarly acting drugs.

    Contraindications:
    Increased individual sensitivity to any of the components of the drug, angle-closure glaucoma, mechanical narrowing (stenosis) of the gastrointestinal tract, megacolon, obstruction of the gastrointestinal tract.

    Children under 3 years.

    Carefully:Care should be taken when prescribing the drug for prostatic hyperplasia, urinary retention, heart rhythm disturbances, elderly patients (especially when there is organic brain symptoms), and patients prone to epileptic seizures.
    Pregnancy and lactation:

    Since the experience of using the drug Akineton ® during pregnancy is limited, the drug should be prescribed after a thorough evaluation of the risk / benefit for the mother and fetus, especially in the first trimester.

    The drug Akineton ® is excreted in breast milk, in which its concentrations can reach the concentrations observed in the blood plasma, therefore, breastfeeding should be discarded.

    Dosing and Administration:

    Treatment with the drug Akineton® usually begins with small doses, gradually increasing them, depending on the therapeutic effect and side effects.

    Parkinson's Syndrome the adults:

    Adults - 1 mg orally 1-2 times a day (1/2 tablet). The dose can be increased by 2 mg (1 tablet) every day. The maintenance dose is 3-16 mg / day (1 / 2-2 tablets 3-4 times a day). The maximum daily dose is 16 mg (8 tablets). The total daily dose should be evenly divided into doses for use during the day. After reaching the optimal dose, patients should be transferred to the drug Akineton® retard tablets.

    Extrapyramidal symptoms in children and adults, caused by the action of drugs: depending on the severity of the symptoms, adults are prescribed 1-4 mg (1 / 2-2 tablets) from one to four times a day as a corrector of neuroleptic therapy.

    Children aged 3-15 years prescribe 1-2 mg (1 / 2-1 tablet) from one to three times a day.

    The drug should be taken during or after eating, squeezed with liquid.

    Unwanted side effects from the gastrointestinal tract can be reduced by taking the pill right after eating.

    The duration of treatment depends on the type of disease.

    When canceling Akinetone ®, its dosage should be gradually reduced.

    The experience with the drug Akineton ® in the treatment of dystonia in children is limited to short courses of treatment with the drug.

    Side effects:

    From the central nervous system (CNS): dizziness, drowsiness, weakness, fatigue, anxiety, confusion, euphoria, memory impairment and in some cases hallucinations, delirious disorders; nervousness, headache, insomnia, dyskinesia, ataxia, muscle cramps and speech impairment. With increased excitation of the nervous system, especially in patients with impaired cerebral function, it is necessary to reduce the dose of the drug.

    Other side effects: dry mouth, salivary gland enlargement, paresis of accommodation, mydriasis accompanied by photophobia, decreased sweating, constipation, epigastric discomfort, nausea, tachycardia and bradycardia, lowering of arterial pressure, difficulty urinating, especially in patients with prostate adenoma (in this case it is recommended to reduce dose) and, more rarely, urinary retention (antidote - carbachole), zakratougolnaya glaucoma (should regularly monitor intraocular pressure), allergic reactions, drug dependence.

    Overdose:

    Symptoms: dilated, slowly reacting to light pupils (mydriasis); dryness of mucous membranes; redness of the skin, palpitations; atony of the bladder and intestines; hyperthermia, especially in children and agitation, confusion, delirium, collapse.

    Treatment: antidote - inhibitors of acetylcholinesterase and, above all, physostigmine. If necessary, catheterization of the bladder. Symptomatic therapy.

    Interaction:

    The use of the drug Akineton ® in combination with other anticholinergic psychotropic drugs, with antihistamines,antiparkinsonian and anticonvulsant drugs can enhance the central and peripheral side effects.

    Simultaneous administration of quinidine may cause an increase in anticholinergic cardiovascular effects (especially atrioventricular conduction).

    Simultaneous appointment with levodopa can enhance dyskinesia.

    Anticholinergics can increase the central side effects of pethidine.

    When treating the drug, the oppressive effect of alcohol on the central nervous system increases.

    Akineton ® weakens the effect of metoclopramide and similarly acting agents on the gastrointestinal tract.

    Special instructions:

    Warnings:

    Side effects are observed, especially in the early stages of treatment and with too rapid a rise in the dose.

    Except for life-threatening complications, abrupt withdrawal of drug treatment should be avoided.

    In elderly patients, especially those having cerebral vascular or degenerative disorders, an increased sensitivity to the drug may often appear.

    Anticholinergic drugs of central action, similar to the drug Akineton®, may increase the predisposition to epileptic seizures. Therefore, doctors should take this fact into consideration when treating patients with this predisposition.

    Late dyskinesia caused by neuroleptics may be intensified by the drug Akineton®.

    Parkinsonian symptoms in the case of advanced tardive dyskinesia in some cases are so severe that they prevent the continuation of treatment with anticholinergic drugs.

    Abuse of the drug Akineton ® was noted. This phenomenon is possibly associated with improved mood and temporary euphoric effects of this drug, which are occasionally observed.

    For prolonged therapy with the drug Akineton®, intraocular pressure should be checked regularly.

    Effect on the ability to drive transp. cf. and fur:Taking Akineton ® and especially in combination with other central drugs, anticholinergics or alcohol can disrupt the ability to drive and work with machinery.
    Form release / dosage:

    Tablets, 2 mg.

    Packaging:

    For 10 or 20 tablets in a blister of PVC / aluminum foil (with perforated to separate the required number of tablets or without perforation).

    2 blisters (10 or 20 tablets in a blister), or 5 blisters (10 or 20 tablets in a blister), or 10 blisters (10 tablets in a blister) are placed with instructions for use.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years.

    Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:П N015243 / 01
    Date of registration:15.08.2007
    Expiration Date:Unlimited
    The owner of the registration certificate: Desma GmbH Desma GmbH Germany
    Manufacturer: & nbsp
    Representation: & nbspDESMA GmbH DESMA GmbH Germany
    Information update date: & nbsp24.06.2017
    Illustrated instructions
      Instructions
      Up